Recent Updates
Recently added Catalysts

SOLX

Phase 1

Blood Donors | Small molecule | Other |Haemonetics Corporation|Last Updated: Apr 25, 2022

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedCONTROLLED
Total Trials1
Total Enrollment170
FDA Designations
No designations recorded
Clinical trial landscape

SOLX · 1 trial · 1 indication

Phase 1 1
NCT02145507Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive SolutionBlood Donors
COMPLETED170 Analytics
PHASE1COMPLETED
Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution
Blood DonorsUnlock trial analytics
Study Endpoints
Primary Endpoints
Red Blood Cell Post-filtration Recovery
Arm and product dependent (< 8 hours, 20-24 hours, 66-72 hours post collection)

The percent of recovered red blood cells when the content of pre-filtration whole blood is compared to the post-filtration leukoreduced whole blood content.

Residual Leukocyte Count
<8 hours and 20-24 hours

The level of residual white blood cells in whole blood filtered after either \<8 hours (AS-3) or 20-24hours (SOLX) of room temperature storage or cold storage for 72 hours.

Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeSUPPORTIVE_CARE
Treatment Arms
ArmTypeDescription
Arm 1: Room Temperature Storage/FiltrationOTHERSOLX (Investigational Product) and AS-3 (Control)
Arm 2 : Cold storageOTHERSOLX (Investigational Product) and AS-3 (Control)
Interventions
NameTypeDescription
SOLX (Investigational)DRUGSOLX is regulated as a drug but is not intended to provide a direct therapeutic benefit.
AS-3 (Control)DRUGAS-3 solution is regulated as a drug but is not intended to provide a direct therapeutic benefit
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria: * Age - Study donor must be ≥ 18 years of age * Weight - Study donor must be ≥ 110 pounds * Temperature - Study donor's body temperature must be ≤ 37.5°C / 99.5°F (oral) * Hemoglobin - Study donor's hemoglobin must be ≥12.5 g/dL * Hematocrit - Study donor's hematocrit must be ≥ ...

Countries:United States
Unlock Eligibility Criteria